Sutro Biopharma, Inc. (STRO)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGM
20.45 USD
-0.86
(-4.036%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 20.45 |
Hot Take ↕ | Aug. 22, 2026, 3:17 a.m. EDT
The investment case for Sutro Biopharma is currently broken by a catastrophic multi-year decline in share price and deteriorating fundamentals. Over the last six years, the stock has lost nearly 90% of its value, driven by four consecutive years of negative annual returns, including a staggering 81% drop last year. The business is bleeding cash, with negative free cash flow and shrinking revenues, while the balance sheet shows negative book value. Despite a 'strong buy' analyst recommendation based on potential future catalysts, the market has priced in severe distress, and the options data confirms this pessimism with heavy put buying and minimal call interest. There is no margin of safety here; the price reflects a deep structural decline rather than a temporary dislocation. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.098734 |
| AutoETS | 0.103426 |
| MSTL | 0.104703 |
| AutoARIMA | 0.182833 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 0.41 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.272 |
| Excess Kurtosis | -1.15 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 3.915 |
| Market Cap | 339,084,960 |
| Forward P/E | -3.29 |
| Beta | 1.52 |
| Website | https://www.sutrobio.com |
As of Aug. 22, 2026, 3:17 a.m. EDT: Speculators are heavily positioned for downside protection, with put open interest significantly outweighing call open interest across all expirations. The bulk of put volume and open interest clusters at strikes below the current price (15.0 and 17.5), indicating a strong bearish bias. Conversely, call activity is sparse, with notable open interest only at distant strikes (35.0 and 40.0), suggesting limited speculative hope for a near-term recovery.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.2431579 |
| Address1 | 111 Oyster Point Boulevard |
| All Time High | 283.0 |
| All Time Low | 5.2 |
| Ask | 31.7 |
| Ask Size | 2 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 249,690 |
| Average Daily Volume3 Month | 342,016 |
| Average Volume | 342,016 |
| Average Volume10Days | 249,690 |
| Beta | 1.515 |
| Bid | 18.57 |
| Bid Size | 2 |
| Book Value | -4.037 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 20.45 |
| Current Ratio | 3.32 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 21.56 |
| Day Low | 20.28 |
| Display Name | Sutro Biopharma |
| Earnings Call Timestamp End | 1,741,899,600 |
| Earnings Call Timestamp Start | 1,741,899,600 |
| Earnings Timestamp End | 1,755,298,800 |
| Earnings Timestamp Start | 1,754,953,200 |
| Ebitda | -125,795,000 |
| Ebitda Margins | -2.75251 |
| Enterprise To Ebitda | -1.475 |
| Enterprise To Revenue | 4.059 |
| Enterprise Value | 185,521,952 |
| Eps Current Year | -7.77 |
| Eps Forward | -6.2125 |
| Eps Trailing Twelve Months | -16.62 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 650 553 9659 |
| Fifty Day Average | 25.7054 |
| Fifty Day Average Change | -5.2553997 |
| Fifty Day Average Change Percent | -0.2044473 |
| Fifty Two Week Change Percent | 124.31579 |
| Fifty Two Week High | 43.85 |
| Fifty Two Week High Change | -23.399998 |
| Fifty Two Week High Change Percent | -0.53363734 |
| Fifty Two Week Low | 7.15 |
| Fifty Two Week Low Change | 13.300001 |
| Fifty Two Week Low Change Percent | 1.86014 |
| Fifty Two Week Range | 7.15 - 43.85 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,538,055,000,000 |
| Float Shares | 10,766,154 |
| Forward Eps | -6.2125 |
| Forward P E | -3.2917507 |
| Free Cashflow | -100,756,000 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 128 |
| Fullday Change | -0.859999 |
| Fullday Change Percent | -4.03566 |
| Fullday Price | 20.45 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | -2.1671 |
| Gross Profits | -99,041,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02258 |
| Held Percent Institutions | 0.98570997 |
| Implied Shares Outstanding | 16,581,171 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,764,720,000 |
| Last Split Factor | 1:10 |
| Long Business Summary | Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease in adults and adults and infants; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California. |
| Long Name | Sutro Biopharma, Inc. |
| Market | us_market |
| Market Cap | 339,084,960 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_38768157 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -180,636,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 354,422,530 |
| Number Of Analyst Opinions | 13 |
| Open | 21.31 |
| Operating Cashflow | -145,172,992 |
| Operating Margins | -3.0172799 |
| Payout Ratio | 0.0 |
| Phone | 650 881 6500 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 20.45 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 21.31 |
| Price Eps Current Year | -2.6319177 |
| Price Hint | 2 |
| Price To Book | -5.065643 |
| Price To Sales Trailing12 Months | 7.4194775 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.216 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.42857 |
| Region | US |
| Regular Market Change | -0.859999 |
| Regular Market Change Percent | -4.03566 |
| Regular Market Day High | 21.56 |
| Regular Market Day Low | 20.28 |
| Regular Market Day Range | 20.28 - 21.56 |
| Regular Market Open | 21.31 |
| Regular Market Previous Close | 21.31 |
| Regular Market Price | 20.45 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 143,817 |
| Return On Assets | -0.36081 |
| Revenue Growth | -0.846 |
| Revenue Per Share | 3.915 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 16,581,171 |
| Shares Percent Shares Out | 0.111899994 |
| Shares Short | 1,855,694 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 1,652,824 |
| Short Name | Sutro Biopharma, Inc. |
| Short Percent Of Float | 0.11229999 |
| Short Ratio | 5.95 |
| Source Interval | 15 |
| State | CA |
| Symbol | STRO |
| Target High Price | 61.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 47.23077 |
| Target Median Price | 50.0 |
| Total Cash | 164,346,000 |
| Total Cash Per Share | 9.912 |
| Total Debt | 10,783,000 |
| Total Revenue | 45,702,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -16.62 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 21.89865 |
| Two Hundred Day Average Change | -1.4486485 |
| Two Hundred Day Average Change Percent | -0.06615241 |
| Type Disp | Equity |
| Volume | 143,817 |
| Website | https://www.sutrobio.com |
| Zip | 94,080 |